
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways is well-positioned for success in the near-term, with a cash runway until 2028 and an accelerated launch path that is expected to offset any potential increase in commercial spending. Additionally, the company's focus on treatment-resistant depression and its strong commercial infrastructure strategy give it a competitive advantage in the space. Management's emphasis on potential strategic partnerships and its confident stance on defending its intellectual property position are also positive indicators for the company's future success.
Bears say
Compass Pathways is facing a challenging market as a growing number of competitors enter the psychedelic medicine field, with many different approaches and treatments for mental health disorders. While the company has invested in building capabilities for their specific therapy, the expanding landscape may make it difficult for them to stand out and compete. Additionally, recent regulatory changes may open the door for other companies to enter the market, potentially creating further competition and pricing pressures for Compass Pathways' treatment. However, the company's Phase 3 trials and growing network of certified sites could give them an advantage in the near-term, and their focus on treatment-resistant depression could work in their favor as a unique offering. Investors should closely monitor the outcome of ongoing clinical trials and any potential changes in the regulatory landscape, which could significantly impact the company's future success.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares